BACKGROUND: Dolutegravir has been widely available in Brazil since 2017. Following the signal that infants born to women with dolutegravir exposure at conception in Botswana had a higher risk of neural tube defects (NTDs), public health leaders initiated a national investigation to evaluate periconception dolutegravir exposure among all pregnant Brazilian women with HIV and its potential association with risk of NTDs, stillbirth, or miscarriage before 22 weeks (also called spontaneous abortion). METHODS: In this retrospective, observational, national, cohort study, we identified all women with pregnancies and possible dolutegravir exposure within 8 weeks of estimated date of conception between Jan 1, 2017, and May 31, 2018, and approximately 3:1 matched pregnant women exposed to efavirenz between Jan 1, 2015, and May 31, 2018, using the Brazilian antiretroviral therapy database. We did detailed chart reviews for identified women. The primary outcomes were NTD and a composite measure of NTD, stillbirth, or miscarriage. NTD incidences were calculated with 95% CI. The composite outcome was examined with logistic regression using propensity score matching weights to balance confounders. FINDINGS: Of 1427 included women, 382 were exposed to dolutegravir within 8 weeks of estimated date of conception. During pregnancy, 183 (48%) of 382 dolutegravir-exposed and 465 (44%) of 1045 efavirenz-exposed women received folic acid supplementation. There were 1452 birth outcomes. There were no NTDs in either dolutegravir-exposed (0, 95% CI 0-0·0010) or efavirenz-exposed groups (0, 95% CI 0-0·0036). There were 23 (6%) stillbirths or miscarriages in 384 dolutegravir-exposed fetuses and 28 (3%) in the 1068 efavirenz-exposed fetuses (p=0·0037). Logistic regression models did not consistently indicate an association between dolutegravir exposure and risk of stillbirths or miscarriages. After study closure, two confirmed NTD outcomes in fetuses with periconception dolutegravir exposure were reported to public health officials. An updated estimate of NTD incidence incorporating these cases and the estimated number of additional dolutegravir-exposed pregnancies between Jan 1, 2015 and Feb 28, 2019, is 0·0018 (95% CI 0·0005-0·0067). INTERPRETATION: Neither dolutegravir nor efavirenz exposure was associated with NTDs in our national cohort; incidence of NTDs is probably well under 1% in dolutegravir-exposed HIV-positive women but still slightly above HIV-uninfected women (0·06%) in Brazil. FUNDING: The Brazilian Ministry of Health and the United States' National Institutes of Health.
BACKGROUND: Dolutegravir has been widely available in Brazil since 2017. Following the signal that infants born to women with dolutegravir exposure at conception in Botswana had a higher risk of neural tube defects (NTDs), public health leaders initiated a national investigation to evaluate periconception dolutegravir exposure among all pregnant Brazilian women with HIV and its potential association with risk of NTDs, stillbirth, or miscarriage before 22 weeks (also called spontaneous abortion). METHODS: In this retrospective, observational, national, cohort study, we identified all women with pregnancies and possible dolutegravir exposure within 8 weeks of estimated date of conception between Jan 1, 2017, and May 31, 2018, and approximately 3:1 matched pregnant women exposed to efavirenz between Jan 1, 2015, and May 31, 2018, using the Brazilian antiretroviral therapy database. We did detailed chart reviews for identified women. The primary outcomes were NTD and a composite measure of NTD, stillbirth, or miscarriage. NTD incidences were calculated with 95% CI. The composite outcome was examined with logistic regression using propensity score matching weights to balance confounders. FINDINGS: Of 1427 included women, 382 were exposed to dolutegravir within 8 weeks of estimated date of conception. During pregnancy, 183 (48%) of 382 dolutegravir-exposed and 465 (44%) of 1045 efavirenz-exposed women received folic acid supplementation. There were 1452 birth outcomes. There were no NTDs in either dolutegravir-exposed (0, 95% CI 0-0·0010) or efavirenz-exposed groups (0, 95% CI 0-0·0036). There were 23 (6%) stillbirths or miscarriages in 384 dolutegravir-exposed fetuses and 28 (3%) in the 1068 efavirenz-exposed fetuses (p=0·0037). Logistic regression models did not consistently indicate an association between dolutegravir exposure and risk of stillbirths or miscarriages. After study closure, two confirmed NTD outcomes in fetuses with periconception dolutegravir exposure were reported to public health officials. An updated estimate of NTD incidence incorporating these cases and the estimated number of additional dolutegravir-exposed pregnancies between Jan 1, 2015 and Feb 28, 2019, is 0·0018 (95% CI 0·0005-0·0067). INTERPRETATION: Neither dolutegravir nor efavirenz exposure was associated with NTDs in our national cohort; incidence of NTDs is probably well under 1% in dolutegravir-exposed HIV-positive women but still slightly above HIV-uninfected women (0·06%) in Brazil. FUNDING: The Brazilian Ministry of Health and the United States' National Institutes of Health.
Authors: Lorena Barbosa; Davianne de Queiroz Ribeiro; Flávio Cunha de Faria; Luciana Neri Nobre; Angelina do Carmo Lessa Journal: Rev Bras Ginecol Obstet Date: 2011-09
Authors: Mmakgomo M Raesima; Chibuike M Ogbuabo; Vasavi Thomas; Sara E Forhan; Gadzikanani Gokatweng; Eldah Dintwa; Chipo Petlo; Catherine Motswere-Chirwa; Elizabeth M Rabold; Sarah C Tinker; Shifawu Odunsi; Sifelani Malima; Omphemetse Mmunyane; Thusoetsile Modise; Kelame Kefitlhile; Kunle Dare; Mpho Letebele; Michelle E Roland; Cynthia A Moore; Surbhi Modi; Dhelia M Williamson Journal: N Engl J Med Date: 2019-07-22 Impact factor: 91.245
Authors: Aastha Gupta; Sandeep Juneja; Marco Vitoria; Vincent Habiyambere; Boniface Dongmo Nguimfack; Meg Doherty; Daniel Low-Beer Journal: PLoS One Date: 2016-10-13 Impact factor: 3.240
Authors: Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Mompati Mmalane; Max Essex; Tendani Gaolethe; Chipo Petlo; Shahin Lockman; Lewis B Holmes; Joseph Makhema; Roger L Shapiro Journal: Lancet Glob Health Date: 2018-06-04 Impact factor: 26.763
Authors: Leonor Maria Pacheco Santos; Roberto Carlos Reyes Lecca; Juan Jose Cortez-Escalante; Mauro Niskier Sanchez; Humberto Gabriel Rodrigues Journal: Bull World Health Organ Date: 2015-10-27 Impact factor: 9.408
Authors: Matthew L Romo; Rena C Patel; Jessie K Edwards; John M Humphrey; Beverly S Musick; Caitlin Bernard; Mercy W Maina; Ellen Brazier; Barbara Castelnuovo; Jeremy Penner; Katarzyna Wyka; Sandra Wagner Cardoso; Penh Sun Ly; Cordelia Kunzekwenyika; Claudia P Cortés; Radoslaw Panczak; Elizabeth A Kelvin; Kara K Wools-Kaloustian; Denis Nash Journal: Ann Intern Med Date: 2021-11-30 Impact factor: 51.598
Authors: Catherine J Wedderburn; Nynke A Groenewold; Annerine Roos; Shunmay Yeung; Jean-Paul Fouche; Andrea M Rehman; Diana M Gibb; Katherine L Narr; Heather J Zar; Dan J Stein; Kirsten A Donald Journal: J Int AIDS Soc Date: 2022-01 Impact factor: 6.707